The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer—A multicenter, randomized, phase III trial.
 
Florian Heitz
Honoraria - AstraZeneca; Roche; Tesaro/GSK
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Novocure; PharmaMar; Roche
Research Funding - Amedes (Inst); AstraZeneca (Inst)
 
Christian Marth
Honoraria - Amgen; AstraZeneca; GlaxoSmithKline; MSD; Novartis; PharmaMar; Roche; Seagen
Consulting or Advisory Role - Amgen; AstraZeneca; GlaxoSmithKline; MSD; Novartis; PharmaMar; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Stephanie Henry
Consulting or Advisory Role - AstraZeneca; BMSi; Gilead Sciences; Merck; MSD Oncology; Novartis; Sanofi; Sanofi
Travel, Accommodations, Expenses - MSD Oncology; Roche
 
Alexander Reuss
No Relationships to Disclose
 
David Cibula
Consulting or Advisory Role - Akeso Biopharma; AstraZeneca; GlaxoSmithKline; Mersana; MSD; Novocure; Roche; Sotio
 
Lydia Gaba
Consulting or Advisory Role - AstraZeneca Spain; Clovis Oncology; GlaxoSmithKline; MSD Oncology; PharmaMar
Travel, Accommodations, Expenses - GlaxoSmithKline/Tesaro; MSD/AstraZeneca
 
Nicoletta Colombo
Employment - Sarepta Therapeutics (I)
Honoraria - Advaxis; Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novartis; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro
Consulting or Advisory Role - Advaxis; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro
 
Sandra Polleis
No Relationships to Disclose
 
Philipp Harter
Honoraria - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Lilly; MSD Oncology; Roche; Sotio; Stryker; Zai Lab
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Immunogen; Merck; Roche; Tesaro
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Roche (Inst)